EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSOTSG00005015974
Gene Symbol: CHRNA4
1 Cross references
136 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSOTSG00005040039
Gene Symbol: CHRNB2
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSOTSG00005046956
Gene Symbol: CHRNB4
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSOTSG00005040725
Gene Symbol: CHRNB4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSOTSG00005034173
Gene Symbol: CHRM2A
1 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSOTSG00005008457
Gene Symbol: CHRM5A
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOTSG00005000506
Gene Symbol: CHRM5B
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSOTSG00005044774
Gene Symbol: CHRNA4B
1 Cross references
191 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSOTSG00005016969
Gene Symbol: CHRNA7A
1 Cross references
204 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOTSG00005011630
Gene Symbol: F2R
1 Cross references
257 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOTSG00005035389
Gene Symbol: F2R
1 Cross references
257 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOTSG00005013617
Gene Symbol: F3
1 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).